Aurobindo Pharma Limited
AUROPHARMA
Pozycja w akcjach
#2072
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Cena akcji
$17.34
Kapitalizacja rynkowa
$9.98B
Zmiana (1 dzień)
-3.08%
Zmiana (1 rok)
38.71%
Kraj
IN
Handel Aurobindo Pharma Limited (AUROPHARMA)
Kategoria
Healthcare
Zyski dla Aurobindo Pharma Limited (AUROPHARMA)
Zyski w Jun 2026 TTM: $598.16M
Według najnowszych raportów finansowych Aurobindo Pharma Limited, obecny zysk firmy wynosi $598.16M. W roku 2024 firma osiągnęła zysk w wysokości $525.28M, wzrost w porównaniu do zysku z roku 2023, który wynosił $317.90M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Aurobindo Pharma Limited od 2004 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $598.16M | 0.98% |
| 2025 | $592.37M | 12.77% |
| 2024 | $525.28M | 65.24% |
| 2023 | $317.90M | -28.45% |
| 2022 | $444.31M | -55.71% |
| 2021 | $1.00B | 101.91% |
| 2020 | $496.85M | 11.61% |
| 2019 | $445.18M | -10.57% |
| 2018 | $497.80M | 5.47% |
| 2017 | $471.99M | 13.94% |
| 2016 | $414.23M | 19.23% |
| 2015 | $347.42M | -3.94% |
| 2014 | $361.67M | 425.28% |
| 2013 | $68.85M | -263.95% |
| 2012 | $-42.00M | -123.75% |
| 2011 | $176.86M | 5.59% |
| 2010 | $167.49M | 1,070.92% |
| 2009 | $14.30M | -80.38% |
| 2008 | $72.91M | 53.10% |
| 2007 | $47.62M | 115.32% |
| 2006 | $22.12M | 427.99% |
| 2005 | $4.19M | -88.08% |
| 2004 | $35.14M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 195.00% |
IN
|
